№ lp_1_2_51168
File format: docx
Character count: 37691
File size: 237 KB
This document provides an updated, detailed list of hereditary dystonia types, including associated clinical clues, genetic information, and mode of inheritance for each subtype.
Year:
2026
Region / city:
N/A
Topic:
Hereditary Dystonia
Document type:
Medical classification list
Organization:
N/A
Author:
N/A
Target audience:
Medical professionals, researchers in genetics and neurology
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
Missouri
Topic:
Hereditary Angioedema Treatment
Document Type:
Proposal
Institution:
MO HealthNet
Author:
MO HealthNet and Conduent
Target Audience:
Health professionals and stakeholders in the MO HealthNet program
Effective Period:
Starting from May 9, 2019
Approval Date:
January 20, 2026
Modification Date:
Not specified
Document Status:
Revision of Existing Criteria
Context:
A proposal outlining the preferred drug list and approval criteria for hereditary angioedema treatment agents within the MO HealthNet program.
Document type:
Press release
Topic:
Rare diseases; hereditary angioedema
Event:
hae day :-)
Date:
16 May
Geographic scope:
Global
Organizing body:
HAE International (HAEi)
Organizational type:
Global non-profit network of patient associations
Target audiences:
General public; healthcare professionals; healthcare decision-makers; industry representatives
Key activity:
Global physical and wellbeing activities converted into steps
Campaign theme:
#active4HAE in purple
Campaign period:
Early April to end of May
Medical condition described:
Hereditary angioedema
Risks described:
Potential fatal airway swelling
Supporting organizations:
National HAE patient organizations
Primary spokesperson cited:
President of HAE International
Online platform referenced:
haeday.org
Press material section:
Notes to editors; About hae day :-); About HAEi
Source type:
Organizational public communication announcing a global health awareness campaign coordinated by an international patient advocacy network and describing planned activities, medical background, and participation framework.
Document Type:
Letter template
Subject:
Request for approval of Guideline-based Hereditary Cancer Panel
Test Name:
Guideline-based Hereditary Cancer Panel
Test Code:
38611
Provider:
Quest Diagnostics
Referenced Organization:
National Comprehensive Cancer Network
Referenced Guidelines:
NCCN Clinical Practice Guidelines in Oncology
Genes Analyzed:
32 cancer-susceptibility genes
CPT Codes:
Listed in Appendix 2
Appendices:
Appendix 1 (Genes included); Appendix 2 (CPT codes)
Intended Author:
Physician (MD)
Intended Recipient:
Payer / Insurance Provider
Date:
1/18/21
Title:
Sample Letter of Medical Necessity – MyRisk Hereditary Cancer Test
Type of Document:
Template letter
Purpose:
Insurance coverage request for genetic testing
Test Name:
MyRisk Hereditary Cancer test
Company:
Myriad Genetics
Referenced Organization:
National Comprehensive Cancer Network
Clinical Focus:
Hereditary breast and ovarian cancer; Lynch syndrome; Familial polyposis; hereditary colorectal cancer
Intended Author:
Healthcare provider / Physician
Intended Recipient:
Medical Director
Subject Matter:
Genetic testing; hereditary cancer syndromes; medical management decisions
Referenced Guidelines:
NCCN Clinical Practice Guidelines in Oncology
Consent Requirement:
Informed consent documented
Related Test Panel:
MyRisk Hereditary Cancer test
Year:
2019
Region / city:
Cambridge, United Kingdom
Topic:
Hereditary diffuse gastric cancer, endoscopic surveillance, biopsy techniques
Document type:
Clinical Trial Study
Organization / institution:
University of Cambridge
Target audience:
Medical professionals, researchers, and clinicians involved in hereditary cancer surveillance
Period of action:
October 2017 - December 2018
Approval date:
Not specified
Date of changes:
Not specified
Note:
Date
Theme:
Hereditary cancer genetic testing
Document type:
Medical necessity letter
Organization / Institution:
Ambry Genetics Corporation
Author:
Ordering Clinician
Target Audience:
Insurance companies, Utilization Review Department
Period of validity:
Until approved
Year:
2026
Location:
London, UK
Subject:
Distal Hereditary Motor Neuropathy, muscle function, gait analysis, rehabilitation
Document Type:
Participant Information Sheet
Institution:
Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery
Chief Investigator:
Dr Gita Ramdharry
Researcher:
Aljwhara Alangary
Target Audience:
Patients with distal hereditary motor neuropathy
Study Duration:
16 months
Measurement Sessions:
0 months, 12 months, 16 months
Intervention:
4-month therapeutic exercise program, ankle braces, physical therapy
Data Collection Methods:
Gait analysis, muscle strength measurement, MRI scans
Consent Required:
Yes
Confidentiality:
Maintained according to privacy regulations; data may be shared anonymously for future research
Country:
United Kingdom
Topic:
Hereditary angioedema and acquired C1 inhibitor deficiency
Document type:
Medical research article
Study type:
National survey
Authors:
Patrick FK Yong; Tanya Coulter; Tariq El-Shanwany; Tomaz Garcez; Scott Hackett; Rashmi Jain; Sorena Kiani-Alikhan; Ania Manson; Sadia Noorani; Catherine Stroud; Christine Symons; Ravishankar Sargur; Cathal Steele; Hana Alachkar; Ariharan Anantharachagan; Peter D Arkwright; Jolanta Bernatoniene; Malini Bhole; Lindsay Brown; Matthew Buckland; Siobhan Burns; Charu Chopra; James Darroch; Elizabeth Drewe; Jillian Edmonds; Anjali Ekbote; Shuayb Elkhalifa; Sarah Goddard; Dorothea Grosse-Kreul; Padmalal Gurugama; Rosie Hague; Richard Herriot; Archana Herwadkar; Stephen M Hughes; Laura Jones; Sara Lear; Elizabeth McDermott; Sai Hurng Kham Murng; Arthur Price; Vyanka Redenbaugh; Alex Richter; Andrew Riordan; Fiona Shackley; Julia Stichbury; Debbie Springett; Michael D Tarzi; Moira Thomas; Pavaladurai Vijayadurai; Austen Worth
Institutions:
Multiple NHS trusts and university hospitals across England, Scotland, Wales, and Northern Ireland
Corresponding author:
Patrick FK Yong
Corresponding institution:
Frimley Health NHS Foundation Trust
Methodology:
Questionnaire survey of specialist centres managing hereditary angioedema and acquired C1 inhibitor deficiency
Number of participating centres:
37
Patient population:
Individuals with HAE-1/2, HAE with normal C1 inhibitor, and acquired C1 inhibitor deficiency
Sample size:
1265 patients
Medical conditions studied:
Hereditary angioedema; acquired C1 inhibitor deficiency
Key treatments mentioned:
Danazol; C1 inhibitor replacement therapy; icatibant; tranexamic acid
Funding source:
Unrestricted grant from Pharming
Keywords:
hereditary angioedema; acquired C1 inhibitor deficiency; epidemiology; demographics; treatment modalities; United Kingdom
Year:
2026
Region:
International
Topic:
Genetic neurological disorders
Document type:
Reference list
Institution:
Medical genetics research
Authors:
Multiple contributors
Target audience:
Clinicians, researchers, geneticists
Data coverage:
Hereditary myoclonus syndromes, gene associations, clinical features
Classification:
By gene, OMIM number, mode of inheritance
Clinical features included:
Seizures, myoclonus severity, cognitive impairment, ataxia, visual and auditory symptoms
Intended use:
Medical reference for hereditary myoclonus
Source type:
Scientific database and literature compilation
Updated:
Yes
Year:
2025
Region / City:
Liberty Township, Delaware County, Ohio
Subject:
Zoning regulations
Document Type:
Zoning Resolution
Authority:
Liberty Township Government
Author:
Liberty Township Trustees
Target Audience:
Residents of Liberty Township, Developers, Property Owners
Period of Effect:
From 2025 onward
Approval Date:
XXXXXX, 2025
Date of Amendments:
N/A
Note:
Year
Contextual Description:
A regulatory document providing guidelines for submitting a Notice of Intent for noncontact cooling water discharges under the NPDES General Permit.
Note:
Year
Year:
2026
Region / city:
South Africa
Theme:
Academic funding
Document type:
Application form
Organization / institution:
University of KwaZulu-Natal (UKZN)
Author:
University of KwaZulu-Natal
Target audience:
Academic staff of UKZN
Period of validity:
2025-2026
Approval date:
Not specified
Date of changes:
Not specified
Contextual description:
Application form for academics at UKZN to apply for funding under the University Capacity Development Programme (UCDP) to complete a first Masters or PhD degree.
Year:
2025
Region / City:
South Africa
Theme:
Higher Education, Academic Funding, Research Support
Document Type:
Application Form
Institution:
University of KwaZulu-Natal (UKZN)
Author:
University of KwaZulu-Natal
Target Audience:
Academics, Faculty Members at UKZN
Funding Period:
2025-2025
Approval Date:
N/A
Deadline for Submission:
14 July 2025
) and join the S1NET. For guides with in depth examinations of performance measure definitions, go to:
https://www.milsuite.mil/book/docs/DOC-129783
Table of Contents (Hyperlinks to Sections):
Developing ‘Significant Duties and Responsibilities’ OER Narratives: Notes, Rules, and Instructions OER Narrative Prohibited Techniques, Inconsistencies, No-Go’s: Negative Comment Rules Referred OERs Narrative Comment Examples Block a. APFT and HT/WT Block b. Overall Performance Block c. Character (to include SHARP comments) Block d. Presence Block e. Intellect Block f. Leads Block g. Develops Block h. Achieves Senior Rater Potential Senior Rater Narrative Examples Senior Rater Narrative Comment Examples (for potential, promotion, school, etc.) Successive Assignments Other SR Comments (explanations of anything unusual about OER) Effective Words for Evaluations JUNIOR OFFICER PLATE (DA FORM 67-10-1) NOTE: 2LTs who have NOT completed BOLC, will not receive an OER until they complete BOLC (AC and ARNG; USAR officers can receive an OER before completing BOLC). The FROM date will be their commissioning date. All time until their BOLC graduation will be NONRATED on their first OER. OER PROFILING: OERs: Rater and Senior Rater Profiles are CONSTRAINED, meaning Officers are only allowed to grant 49% of each rank they rate with either an “EXCELS” (as Rater) or “MOST QUALIFIED” (as Senior Rater). HOWEVER, if you have an immature profile, and have only just begun rating/senior rating Officers of a certain rank, you are allowed a ONE TIME option of giving one of the first two evaluations you make at a particular grade, an “EXCELS” (as Rater) or “MOST QUALIFIED” (as Senior Rater). OER (OER SUPPORT FORM) PART III: Developing ‘Significant Duties and Responsibilities’ (blocks a., b., and c.): Refer to DA PAM 611-21 (https://www.milsuite.mil/book/groups/smartbookdapam611-21
) and DA PAM 600-3 (Commissioned Officer Professional Development and Career Management), to assist in the development of PART III, block d. As a minimum, the duty description will include pr:
- Number of personnel supervised, - Amount of resources under the rated officer’s control, - Scope of responsibilities. 3) Descriptions must be clear and concise with emphasis on specific functions required. 4) Note conditions unique to the assignment; e.g. RA officers assigned to FT support duties with RC units or USAR officers assigned to RA units OER NARRATIVES: Notes, Rules, and Instructions Rater and Senior Rater Narratives: - Requires candor and courage; frank and accurate assessment. - Quantify officer’s value relative to peers and do so in concert with rater/senior rater box check. - Are short; tell a simple story about the quality of officer being evaluated. - Are interesting and compelling. - Are looked at by selection board members when they are looking for in-depth information about a rated officer’s performance and potential. - Numbers; 1-10, write them out (e.g. one, two, ten). 11 or higher, write the number; e.g. 11, 15, 105. Exception, when a 1-10 is WITH an 11 or higher; e.g. “5 tool kits with 20 tools each.” - Fashion the narrative to the officer; double check use of “he/his” vs. “she/hers.” - Awards: Awards and/or special recognition received during the rating period may be cited in evaluation comments (for example, “received the Humanitarian Service Medal” or “named the Instructor of the Year”). - Raters and SR CAN use the officer’s name in the narrative; e.g. “1LT Joe was ….” Rater and Rater Narratives: - Focus on PERFORMANCE; explaining what the rated officer did and how well he/she did it. - Focus on specifics to quantify and qualify performance. - Raters should advocate the rated officer to the SR. - When there is no SR (due to lack of qualifications), rater’s narrative provides the input on both performance and potential. Senior Rater (SR) and SR Narrative (see SR Rater Narrative section for examples): - Focus on POTENTIAL, 3-5 years out (promotions, command, school, & assignments). - Can amplify box checks by using the narrative to clearly send the appropriate message to selection boards. - CANNOT mention Box Check. - Additional information for when SR is also Rater can be found in DA PAM 623-3, pg. 26, “DA Form 67–10–1, part VI: block c—Senior Rater Narrative.” OER Narrative Prohibited Techniques, Inconsistencies, No-Go’s: - School/Course Comments: Bullets about how a Soldier did in a school or course are ONLY allowed if that school did not produce an AER/DA Form 1059. - Narratives are not a laundry list of superlatives – more is not necessarily better. - Brief, unqualified superlatives or phrases, particularly if they may be considered trite. - Excessive use of technical acronyms, or phrases not commonly recognized. - Techniques aimed at making specific words, phrases, or sentences stand out from the rest of the narrative; e.g. excessive use of capital letters; unnecessary quotation marks; repeated use of exclamation points; wide spacing between selected words, phrases, or sentences to include double spacing within a paragraph or between paragraphs. - Inappropriate references to box checks; e.g “Would be TOP BLOCK if profile allowed” or “absolutely far exceeded the standard”. - Trying to quantify (e.g. “top 2% of my captains”) with a small population. - Stay in your lane/level; avoid comments like “Best 1LT in the Army” unless you’re the Army CoS. - Stating “the best ever”; having 10 in the population, 50 in the profile. - Using overused phrases and clichés that are counterproductive or overused; e.g. stellar, historic, “delivered a dazzling performance,” “hit the ground running,” consummate professional, and unlimited potential. - Using specific selection board-type language. Examples of this include, “definitely a 6+ Soldier”. - Don’t exaggerate; “If I could prove it, CPT X is an LTC disguised as a CPT.” - Be mindful of what IS NOT said; it can have the same impact as what is said; e.g. NOT having numbers, or quantifiable points. - Don’t say the sa
Note:
en
Topic:
Officer Evaluation, Narrative Guidelines
Document Type:
Guide
Target Audience:
Raters, Senior Raters
Year:
2023
Region / City:
Australia
Topic:
Biogenic carbon cycle, grazing livestock, methane flux, soil carbon
Document Type:
Tender Specification
Organization / Institution:
Meat & Livestock Australia (MLA)
Author:
Not specified
Target Audience:
Organizations or partnerships conducting research
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Note:
Year
Topic:
Complete Streets, Transportation Planning
Document Type:
Decision Document
Organization / Institution:
California Department of Transportation (Caltrans)
Target Audience:
Transportation Planners, Project Engineers, District Coordinators
Year:
2024
Region / City:
Worldwide
Topic:
Accessibility, Screen Reader
Document Type:
User Guide
Organization / Institution:
Microsoft
Author:
Microsoft
Target Audience:
Users with visual impairments
Period of Validity:
Ongoing
Approval Date:
February 2024
Modification Date:
February 2024
Note:
Year
Subject:
Organic certification and handling procedures
Document Type:
Organic certification questionnaire
Organization:
ACO (Australian Certified Organic)
Author:
ACO
Target Audience:
Organic operators
Effective Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Note:
Date
Topic:
Recruitment
Document Type:
Template
Target Audience:
Researchers, Study Participants